Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643221 | 1.00 | MAPT (0.49) | MAPTKMT2AMEN1CNR1KDM4E | |
| SCHEMBL12643198 | 0.93 | KMT2A (0.49) | MAPTKMT2AMEN1CNR1KDM4E | |
| SCHEMBL14668252 | 0.91 | TP53 (0.53) | MAPTKMT2AMEN1CNR1KDM4E | |
| SCHEMBL17636193 | 0.87 | GAA (0.53) | SMOALDH1A1NPC1SLC6A9 | |
| SCHEMBL30511079 | 0.87 | GAA (0.53) | SMOALDH1A1NPC1SLC6A9 | |
| SCHEMBL32672556 | 0.86 | SMO (0.44) | SMONPC1SLC6A9 | |
| SCHEMBL32672541 | 0.84 | SLC6A9 (0.44) | SMOTP53SLC6A9 | |
| SCHEMBL32672593 | 0.83 | SMO (0.47) | KMT2AMEN1SMOTP53ALDH1A1 | |
| SCHEMBL32672552 | 0.82 | SMO (0.47) | MAPTKMT2AMEN1SMOTP53 | |
| SCHEMBL16270375 | 0.81 | SLC6A9 (0.39) | SMONPC1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066722-A1 | METHODS FOR PRODUCTION OF FUNCTIONAL NEURONS | AXENT BIOSCIENCES INC. (US) | 2025-02-27 | — | — | US | claimed |
| EP-4413119-A1 | METHODS FOR PRODUCTION OF FUNCTIONAL NEURONS | Axent Biosciences Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| WO-2023086894-A1 | METHODS FOR PRODUCTION OF FUNCTIONAL NEURONS | AXENT BIOSCIENCES INC. (US) | 2023-05-19 | — | — | WO | claimed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | claimed |
| US-20260076962-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | NIMMUNE BIOPHARMA, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| CN-121577784-A | Method for constructing HPLC (high performance liquid chromatography) characteristic spectrum of medicinal materials, decoction pieces, formula particles and standard decoction of charred Massa Medicata Fermentata and determination of adenine content | 四川新绿色药业科技发展有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4673532-A1 | THERAPY | Plasticell Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| US-20250387362-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | BURZYNSKI STANISLAW R (US) | 2025-12-25 | — | — | US | disclosed |
| US-12502388-B2 | Lanthionine synthetase C-like 2-based therapeutics | NIMMUNE BIOPHARMA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12403712-B2 | Heat-sensitive recording material | Oji Holdings Corporation (JP) | 2025-09-02 | — | — | US | disclosed |
| EP-4568663-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | Burzynski, Stanislaw R. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-116879457-B | Construction method and application of high-efficiency liquid-phase characteristic spectrum of lycopodium clavatum | 四川新绿色药业科技发展有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-11607397-B2 | Methods for the treatment of leptomeningeal disease | STANISLAW R. BURZYNSKI (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4140756-A1 | HEAT-SENSITIVE RECORDING BODY | Oji Holdings Corporation (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-115586279-A | Detection method of Bupleurum falcatum or preparation thereof and construction method of fingerprint spectrum thereof | 四川新绿色药业科技发展有限公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-115515796-A | Thermosensitive recording medium | 王子控股株式会社 | 2022-12-23 | — | — | CN | disclosed |
| EP-3757099-B1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11344521-B2 | Methods for the treatment of leptomeningeal disease | BURZYNSKI, STANISLAW R. | 2022-05-31 | — | — | US | disclosed |
| US-20220072044-A1 | THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH | LANDOS BIOPHARMA, INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072044-A1 | THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH | LCP2, LANCL2, CALCB | MAPT 3690/4885KMT2A 3249/4885MEN1 2022/4885 |
| US-12502388-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | MAPT 3162/4885KMT2A 2759/4885MEN1 919/4885 |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | MAPT 3162/4885KMT2A 2759/4885MEN1 919/4885 |
| US-20260076962-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | SCLY, CLCN2, CBS | MAPT 4651/4885KMT2A 2706/4885MEN1 1564/4885 |
| US-20250387362-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | SLC25A1, GOT2, FOLH1 | MAPT 1391/4885KMT2A 942/4885MEN1 2706/4885 |
| US-11344521-B2 | Methods for the treatment of leptomeningeal disease | CLN6, GALC, GBA1 | MAPT 1648/4885KMT2A 335/4885MEN1 1394/4885 |
| US-11607397-B2 | Methods for the treatment of leptomeningeal disease | CLN6, GALC, GBA1 | MAPT 1648/4885KMT2A 335/4885MEN1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.